News Release

October 30, 2024
JCR Pharmaceuticals Co., Ltd.

Translation

Notice of Distribution of Retained Earnings (Interim Dividend)

Hyogo, Japan, October 30, 2024 -- JCR Pharmaceuticals Co., Ltd. (TSE 4552; Chairman and President: Shin Ashida; "JCR") announced that its Board of Directors resolved at a meeting today to distribute retained earnings (interim dividend) with the record date being September 30, 2024.

1. Details of interim dividends

	Amount decided	Latest forecast for dividend (Released on May 10, 2024)	Actual result for previous interim period (Six months ended September 30, 2023)
Record date	September 30, 2024	September 30, 2024	September 30, 2023
Dividends per share	10.00 yen	10.00 yen	10.00 yen
Total amount of dividends	1,257 million yen	-	1,251 million yen
Effective date	December 6, 2024	-	December 8, 2023
Dividend resource	Retained earnings	-	Retained earnings

2. Reasons

JCR regards the distribution of profits to shareholders as an important management policy. It is the Company's basic policy to distribute cash dividends on a continued, consistent basis by taking into consideration the business performance and cash flow while securing sufficient internal reserves to develop new drug products that will be a source of future profits and to strengthen financial position of the Company.

Guided by the foregoing policy, JCR has declared an interim dividend of 10.00 yen per share for the fiscal year ending March 31, 2025.

3. (Reference) Details of annual dividend forecast

	Dividend per share		
	Interim (End of 2nd quarter)	Year-end	Total
Dividend forecast (fiscal year ending March 31, 2025)	-	10.00 yen	20.00 yen

Actual result for the fiscal year ending March 31, 2025	10.00 yen	-	-
Actual result for the fiscal year ended March 31, 2024	10.00 yen	10.00 yen	20.00 yen

About JCR Pharmaceuticals Co., Ltd.

JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceuticals company that is expanding possibilities for people with rare and genetic diseases worldwide. We continue to build upon our 49-year legacy in Japan while expanding our global footprint into the US, Europe, and Latin America. We improve patients' lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, MPS II (Hunter syndrome), Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), MPS II, MPS IIIA and B (Sanfilippo syndrome type A and B), and more. JCR strives to expand the possibilities for patients while accelerating medical advancement at a global level. Our core values – reliability, confidence, and persistence – benefit all our stakeholders, including employees, partners, and patients. For more information, please visit https://www.jcrpharm.co.jp/en/site/en/.

Cautionary Statement Regarding Forward-Looking Statements

This document contains forward-looking statements that are subject to known and unknown risks and uncertainties, many of which are outside our control. Forward-looking statements often contain words such as "believe," "estimate," "anticipate," "intend," "plan," "will," "would," "target" and similar references to future periods. All forward-looking statements regarding our plans, outlook, strategy and future business, financial performance and financial condition are based on judgments derived from the information available to us at this time. Factors or events that could cause our actual results to be materially different from those expressed in our forward-looking statements include, but are not limited to, a deterioration of economic conditions, a change in the legal or governmental system, a delay in launching a new product, impact on competitors' pricing and product strategies, a decline in marketing capabilities relating to our products, manufacturing difficulties or delays, an infringement of our intellectual property rights, an adverse court decision in a significant lawsuit and regulatory actions.

This document involves information on pharmaceutical products (including those under development). However, it is not intended for advertising or providing medical advice. Furthermore, it is intended to provide information on our company and businesses and not to solicit investment in securities we issue.

Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the factors that could cause actual results to differ materially, even if new information becomes available in the future.

Contact:
Investors & Media:
JCR Pharmaceuticals Co., Ltd.
Corporate Communications
ir-info@jp.jcrpharm.com

###